Cannabinoids have established themselves as therapeutic options in the treatment of pain in recent years. Nevertheless, patients can experience problems when using them, particularly with regard to tolerance. A new aqueous nanodispersion appears to be able to eliminate these problems.
Autoren
- Jens Dehn
Publikation
- InFo RHEUMATOLOGIE
Related Topics
You May Also Like
- Psychooncology
Communication as the key to therapy adherence
- Participation of the patient
Adherence in psychiatry
- From symptom to diagnosis
Renal cell carcinoma
- Lipid management: ESC/EAS guideline update 2025
New recommendations on CVD risk classification, lipid lowering in statin intolerance and hoFH
- Chronically active MS lesions
New paradigm in the diagnosis and treatment of multiple sclerosis
- AI in neurology
Control instead of a flood of data: AI makes big data and wearables usable
- Participation of the patient
Adherence in psychiatry
- Eosinophilic esophagitis